Recent advances in the nanotechnology-based drug delivery of silybin

Journal of Biomedical Nanotechnology

Volumn 10, Issue 4, 2014, Pages 543-558

  Wang, Yancai ^a   Zhang, Ling ^b   Wang, Qiwei ^c   Zhang, Dianrui ^c  

^a SHANDONG POLYTECHNIC UNIVERSITY   (China)

^b SHANDONG UNIVERSITY OF FINANCE AND ECONOMICS   (China)

^c SHANDONG UNIVERSITY   (China)

Author keywords

Bioavailability; Nanoparticles; Nanosuspensions; Nanotechnology; Silybin

Indexed keywords

BIOAVAILABILITY; DRUG DELIVERY SYSTEM; IN-VITRO DISSOLUTION; MILK THISTLE PLANT; NANO-SUSPENSIONS; NATURAL PRODUCTS; SILYBIN; WATER SOLUBILITIES;

BIOCHEMISTRY; DRUG DELIVERY; DRUG PRODUCTS; EMULSIONS; NANOPARTICLES; NANOTECHNOLOGY; PLANTS (BOTANY);

FLAVONOIDS;

BETA CYCLODEXTRIN DERIVATIVE; MESOPOROUS SILICA NANOPARTICLE; NANOPARTICLE; PHOSPHATIDYLCHOLINE; PHOSPHOLIPID; POLYAMIDOAMINE; POROUS SILICA NANOPARTICLE; SILIBININ; SOLID LIPID NANOPARTICLE; UNCLASSIFIED DRUG; VITAMIN; WATER;

BREAST CANCER; CANCER CHEMOTHERAPY; DISPERSION; DRUG BIOAVAILABILITY; DRUG COMBINATION; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG RELEASE; DRUG SOLUBILITY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LIVER DISEASE; MICELLE; NANOEMULSION; NANOTECHNOLOGY; OVARY CANCER; PARTICLE SIZE; PROSTATE CANCER; REVIEW; SELF EMULSIFYING DRUG DELIVERY SYSTEM; SUSPENSION;

ANTIOXIDANTS; CRYSTALLIZATION; EVIDENCE-BASED MEDICINE; HUMANS; LIVER DISEASES; MACROMOLECULAR SUBSTANCES; MATERIALS TESTING; MOLECULAR CONFORMATION; NANOCAPSULES; NEOPLASMS; SILYMARIN; SURFACE PROPERTIES; SUSPENSIONS; TREATMENT OUTCOME;

EID: 84896761926     PISSN: 15507033     EISSN: 15507041     Source Type: Journal    
DOI: 10.1166/jbn.2014.1798     Document Type: Review

References (108)

1. T. C. Bai, G. B. Yan, J. Hu, H. L. Zhang, and C. G. Huang, Solubility of silybin in aqueous poly(ethylene glycol) solution. Int. J. Pharm. 308, 100 (2006).
2. D. Y. W. Lee and Y. Z. Liu, Molecular structure and stereochemistry of silybin A, silybin B, isosilybin A, and isosilybin B, isolated from Silybum marianum (Milk thistle) J. Nat. Prod. 66, 1632 (2003).
3. E. S. Hackett, D. C. Twedt, and D. L. Gustafson, Milk thistle and its derivative compounds: A review of opportunities for treatment of liver disease. J. Vet. Intern. Med. 27, 10 (2013).
4. A. A. Sy-Cordero, T. N. Graf, S. P. Runyon, M. C. Wani, D. J. Kroll, R. Agarwal, S. J. Brantley, M. F. Paine, S. J. Polyak, and N. H. Oberlies, Enhanced bioactivity of silybin B methylation products. Bioorgan. Med. Chem. 21, 742 (2013).
5. K. Purchartova, P. Marhol, R. Gazak, D. Monti, S. Riva, M. Kuzma, and V. Kren, Regioselective alcoholysis of silybin A and B acetates with lipases. J. Mol. Catal. B-Enzym. 71, 119 (2011).
6. J. Y. Zhang, Q. Y. Luan, Y. Z. Liu, D. Y. W. Lee, and Z. Wang, A comparison of the diastereoisomers, silybin A and silybin B, on the induction of apoptosis in K562 cells. Nat. Prod. Commun. 6, 1653 (2011).
7. M. Gharagozloo, Z. Khoshdel, and Z. Amirghofran, The effect of an iron (III) chelator, silybin, on the proliferation and cell cycle of Jurkat cells: A comparison with desferrioxamine. Eur. J. Pharmacol. 589, 1 (2008).
8. P. Zhang, H. Ye, T. Min, and C. Zhang, Water soluble poly(ethylene glycol) prodrug of silybin: Design, synthesis, and characterization. J. Appl. Polym. Sci. 107, 3230 (2008).
9. Y. Kawabata, K. Wada, M. Nakatani, S. Yamada, and S. Onoue, Formulation design for poorly water-soluble drugs based on biopharmaceutics classification system: Basic approaches and practical applications. Int. J. Pharm. 420, 1 (2011).
10. D. Zheng, Y. Wang, D. Zhang, Z. Liu, C. Duan, L. Jia, F. Wang, Y. Liu, G. Liu, L. Hao, and Q. Zhang, In vitro antitumor activity of silybin nanosuspension in PC-3 cells. Cancer Lett. 307, 158 (2011).
11. M. Martinez, L. Augsburger, T. Johnston, and W. W. Jones, Applying the biopharmaceutics classification system to veterinary pharmaceutical products part I: Biopharmaceutics and formulation considerations. Adv. Drug Deliver. Rev. 54, 805 (2002).
12. M. Martinez, G. Amidon, L. Clarke, W. W. Jones, A. Mitra, and J. Riviere, Applying the biopharmaceutics classification system to veterinary pharmaceutical products part II physiological considerations. Adv. Drug Deliver. Rev. 54, 825 (2002).
13. J. He, S. X. Hou, W. G. Lu, L. Zhu, and J. F. Feng, Preparation, pharmacokinetics and body distribution of silymarin-loaded solid lipid nanoparticles after oral administration. J. Biomed. Nanotechnol 3, 195 (2007).
14. R. H. Muller, S. Gohla, and C. M. Keck, State of the art of nanocrystals - Special features, production, nanotoxicology aspects and intracellular delivery. Eur. J. Pharm. Biopharm 78, 1 (2011).
15. W. He, Y. Lu, J. P. Qi, L. Y. Chen, F. Q. Hu, and W. Wu, Food proteins as novel nanosuspension stabilizers for poorly water-soluble drugs. Int. J. Pharm. 441, 269 (2013).
16. B. E. Rabinow, Nanosuspensions in drug delivery. Nat. Rev. Drug Discov. 3, 785 (2004).
17. L. Sievens-Figueroa, A. Bhakay, J. I. Jerez-Rozo, N. Pandya, R. J. Romanach, B. Michniak-Kohn, Z. Iqbal, E. Bilgili, and R. N. Dave, Preparation and characterization of hydroxypropyl methyl cellulose films containing stable BCS class II drug nanoparticles for pharmaceutical applications. Int. J. Pharm. 423, 496 (2012).
18. Y. Wang, Z. Liu, D. Zhang, X. Gao, X. Zhang, C. Duan, L. Jia, F. Feng, Y. Huang, Y. Shen, and Q. Zhang, Development and in vitro evaluation of deacety mycoepoxydiene nanosuspension. Colloid Surface B 83, 189 (2011).
19. Y. Wang, L. Wang, Z. Liu, D. Zhang, and Q. Zhang, In vivo evaluation of silybin nanosuspensions targeting liver. J. Biomed. Nanotechnol. 8, 760 (2012).
20. Y. Wang, D. Zhang, Z. Liu, G. Liu, C. Duan, L. Jia, F. Feng, X. Zhang, Y. Shi, and Q. Zhang, In vitro and in vivo evaluation of silybin nanosuspensions for oral and intravenous delivery. Nanotechnology 21, 155104 (2010).
21. H. K. Chan and P. C. L. Kwok, Production methods for nanodrug particles using the bottom-up approach. Adv. Drug Deliver. Rev. 63, 406 (2011).
22. X. Chen, M. E. Matteucci, C. Y. Lo, K. P. Johnston, and R. O. Williams, 3rd, Flocculation of polymer stabilized nanocrystal suspensions to produce redispersible powders. Drug Dev. Ind. Pharm. 35, 283 (2009).
23. J. Y. Choi, J. Y. Yoo, H. S. Kwak, B. U. Nam, and J. Lee, Role of polymeric stabilizers for drug nanocrystal dispersions. Curr. Appl. Phys. 5, 472 (2005).
24. K. Fuhrmann, M. A. Gauthier, and J. C. Leroux, Crosslinkable polymers for nanocrystal stabilization. J. Control Release 148, 12 (2010).
25. A. Dolenc, J. Kristl, S. Baumgartner, and O. Planinsek, Advantages of celecoxib nanosuspension formulation and transformation into tablets. Int. J. Pharm. 376, 204 (2009).
26. Y. Gao, Z. Li, M. Sun, C. Guo, A. Yu, Y. Xi, J. Cui, H. Lou, and G. Zhai, Preparation and characterization of intravenously injectable curcumin nanosuspension. Drug Deliver. 18, 131 (2011).
27. B. Stark, G. Pabst, and R. Prassl, Long-term stability of sterically stabilized liposomes by freezing and freeze-drying: Effects of cryoprotectants on structure. Eur. J. Pharm. Sci. 41, 546 (2010).
28. N. Bhala, G. Aithal, and J. Ferguson, How to tackle rising rates of liver disease in the UK. Brit. Med. J. 346, 807 (2013).
29. M. A. Ibrahim, M. Kelleni, and A. Geddawy, Nonalcoholic fatty liver disease: Current and potential therapies. Life Sci. 92, 114 (2013).
30. J. Puppala, S. P. Siddapuram, J. Akka, and A. Munshi, Genetics of nonalcoholic fatty liver disease: An overview. J. Genet. Genomics. 40, 15 (2013).
31. M. Rodriguez-Torres, Focus on drug interactions: The challenge of treating hepatitis C virus infection with direct-acting antiviral drugs in the HIV-positive patient. Curr. Opin. Infect. Dis. 26, 50 (2013).
32. G. M. Lauer, Immune responses to hepatitis C virus (HCV) infection and the prospects for an effective HCV vaccine or immunotherapies. J. Infect. Dis. 207, 7 (2013).
33. V. J. Barbero-Becerra and N. Mendez-Sanchez, Silybin/silymarin treatment in chronic hepatitis C. Ann. Hepatol. 11, 731 (2012).
34. C. Loguercio, P. Andreone, M. C. Brisc, M. Chiaramonte, A. Floreani, M. Freni, A. Grieco, S. Lobello, S. Milani, L. Okolicsanyi, P. Portincasa, A. Smedile, I. Sporea, R. Vecchione, C. D. Blanco, and R. Grp, Silybin as supplementary food: A possible cooperative instrument in the management of patients with chronic hepatitis. Eur. J. Clin. Invest. 40, 83 (2010).
35. G. Serviddio, F. Bellanti, A. D. Romano, R. Tamborra, T. Rollo, M. Blonda, D. Bruno, and E. Altomare, A silybin-phospholipid-vitamin E complex (siliphos) prevents oxidation of ucp2 and limits mitochondrial dysfunction during non-alcoholic steatohepatitis. J. Hepatol. 50, 264 (2009).
36. P. Kidd and K. Head, A review of the bioavailability and clinical efficacy of milk thistle phytosome: A silybin-phosphatidylcholine complex (siliphos (R)). Altern. Med. Rev. 10, 193 (2005).
37. Y. M. Song, J. Zhuang, J. X. Guo, Y. Y. Xia, and Q. N. Ping, Preparation and properties of a silybin-phospholipid complex. Pharmazie 63, 35 (2008).
38. M. Narges and M. Nasrin, Comparing the inhibitory effect of Silybin-phosphatidylcholine with silybin in BT474 breast cancer cell line. Clin. Biochem. 44, 203 (2011).
39. F. Bellanti, A. Arduini, R. Tamborra, T. Rollo, M. Blonda, A. D. Romano, J. Sastre, and G. Serviddio, A Silybin-phospholipid complex prevents mitochondrial oxidative stress in models of chronic liver disease. Free Radical. Bio. Med. 49, 177 (2010).
40. A. Di Sario, E. Bendia, S. Taffetani, C. Candelaresi, F. Ridolfi, and A. Benedetti, Realsil, a new silybin-phospatidylcholine complex, reduces dimethylnitrosamine-induced hepatic fibrosis in the rat. J. Hepatol. 38, 76 (2003).
41. A. Di Sario, E. Bendia, S. Taffetani, A. Omenetti, C. Candelaresi, M. Marzioni, S. De Minicis, and A. Benedetti, Hepatoprotective and antifibrotic effect of a new silybin-phosphatidylcholine-vitamin E complex in rats. Dig. Liver Dis. 37, 869 (2005).
42. I. Grattagliano, C. V. Diogo, D. Ferri, D. Q. H. Wang, and P. Portincasa, The silybin-phospholipids-vitamin E complex protects against fatty degeneration, nitrosative and oxidative stress in rat models of liver steatosis. Eur. J. Clin. Invest. 41, 16 (2011).
43. I. Grattagliano, C. V. Diogo, D. Ferri, D. Q. Wang, and P. Portincasa, The silybin-phospholipids-vitamin E complex protects against fatty degeneration, nitrosative and oxidative stress in rat models of liver steatosis. Gastroenterology 140, S985 (2011).
44. C. Loguercio, A. Federico, M. Trappoliere, C. Tuccillo, I. de Sio, A. Di Leva, M. Niosi, M. V. D'Auria, R. Capasso, and C. D. Blanco, The effect of a silybin-vitamin E-phospholipid complex on nonalcoholic fatty liver disease: A pilot study. Dig. Dis. Sci. 52, 2387 (2007).
45. C. Loguercio, P. Andreone, C. Brisc, M. C. Brisc, E. Bugianesi, M. Chiaramonte, C. Cursaro, M. Danila, I. de Sio, A. Floreani, M. A. Freni, A. Grieco, M. Groppo, R. Lazzari, S. Lobello, E. Lorefice, M. Margotti, L. Miele, S. Milani, L. Okolicsanyi, G. Palasciano, P. Portincasa, P. Saltarelli, A. Smedile, F. Somalvico, A. Spadaro, I. Sporea, P. Sorrentino, R. Vecchione, C. Tuccillo, C. Del Vecchio Blanco, and A. Federico, Silybin combined with phosphatidylcholine and vitamin E in patients with nonalcoholic fatty liver disease: a randomized controlled trial. Free Radic. Biol. Med. 52, 1658 (2012).
46. G. Serviddio, F. Bellanti, A. M. Giudetti, G. V. Gnoni, A. Petrella, R. Tamborra, A. D. Romano, T. Rollo, G. Vendemiale, and E. Altomare, A silybin-phospholipid complex prevents mitochondrial dysfunction in a rodent model of nonalcoholic steatohepatitis. J. Pharmacol. Exp. Ther. 332, 922 (2010).
47. G. Serviddio, F. Bellanti, J. Sastre, G. Vendemiale, and E. Altomare, Targeting mitochondria: A new promising approach for the treatment of liver diseases. Curr. Med. Chem. 17, 2325 (2010).
48. M. Y. Zhou, A. M. Xu, P. K. H. Tam, K. S. L. Lam, L. Chan, R. L. C. Hoo, J. Liu, K. H. M. Chow, and Y. Wang, Mitochondrial dysfunction contributes to the increased vulnerabilities of adiponectin knockout mice to liver injury. Hepatology 48, 1087 (2008).
49. G. Serviddio, F. Bellanti, A. D. Romano, R. Tamborra, M. Blonda, and E. Altomare, A silybin-phospholipid-vitamin E complex (siliphos) limits the hepatic damage and reduces oxidative stress in human obesity - Related liver disease. Free Radic. Res. 43, 80 (2009).
50. F. Zoulim and S. Locarnini, Optimal management of chronic hepatitis B patients with treatment failure and antiviral drug resistance. Liver Int. 33, 116 (2013).
51. K. Falasca, C. Ucciferri, P. Mancino, E. Vitacolonna, D. De Tullio, E. Pizzigallo, P. Conti, and J. Vecchiet, Treatment with silybin-vitamin E-phospholipid complex in patients with hepatitis C infection. J. Med. Virol. 80, 1900 (2008).
52. A. Hassan, M. Ragheb, M. Tawfik, and A. W. Hassan, Effectiveness of silybin-phospatidylcholine (IdB1016) complex or silymarin in improving clinical outcome and quality of life in HCV chronic liver disease. Trop. Med. Int. Health 14, 213 (2009).
53. F. Delie, E. Allemann, and M. Cohen, Nanocarriers for ovarian cancer active drug targeting. J. Drug Deliver. Sci. Tec. 22, 421 (2012).
54. H. C. Arora, M. P. Jensen, Y. Yuan, A. G. Wu, S. Vogt, T. Paunesku, and G. E. Woloschak, Nanocarriers enhance doxorubicin uptake in drug-resistant ovarian cancer cells. Cancer Res. 72, 769 (2012).
55. P. Zahedi, R. Yoganathan, M. Piquette-Miller, and C. Allen, Recent advances in drug delivery strategies for treatment of ovarian cancer. Expert Opin. Drug Del. 9, 567 (2012).
56. D. Gallo, S. Giacomelli, C. Ferlini, G. Raspaglio, P. Apollonio, S. Prislei, A. Riva, P. Morazzoni, E. Bombardelli, and G. Scambia, Antitumour activity of the silybin-phosphatidylcholine complex, 1 dB 1016, against human ovarian cancer. Eur. J. Cancer 39, 2403 (2003).
57. D.Gallo, S. Giacomelli,C.Ferlini,G.Raspaglio,D.Travaglia,A.Riva, P. Morazzoni, E. Bombardelli, S. Mancuso, and G. Scambia, The silybin-phospholipid complex ldB 1016 inhibits human ovarian cancer growth in athymic nude mice. Eur. J. Cancer 38, 154 (2002).
58. C. Printz, New drug regimen may help advanced breast cancer patients. Cancer 119, 3 (2013).
59. A. Gopalan, W. P. Yu, B. G. Sanders, and K. Kline, Eliminating drug resistant breast cancer stem-like cells with combination of simvastatin and gamma-tocotrienol. Cancer Lett. 328, 285 (2013).
60. K. R. Kim, D. R. Kim, T. Lee, J. Y. Yhee, B. S. Kim, I. C. Kwon, and D. R. Ahn, Drug delivery by a self-assembled DNA tetrahedron for overcoming drug resistance in breast cancer cells. Chem. Commun. 49, 2010 (2013).
61. M. Provinciali, F. Papalini, F. Orlando, S. Pierpaoli, A. Donnini, P. Morazzoni, A. Riva, and A. Smorlesi, Effect of the silybin-phosphatidylcholine complex (ldB 1016) on the development of mammary tumors in HER-2/neu transgenic mice. Cancer Res. 67, 2022 (2007).
62. P. Vainio, J. P. Mpindi, P. Kohonen, V. Fey, T. Mirtti, K. A. Alanen, M. Perala, O. Kallioniemi, and K. Iljin, High-throughput transcriptomic and RNAi analysis identifies AIM1, ERGIC1, TMED3 and TPX2 as potential drug targets in prostate cancer. Plos One 7 (2012).
63. A. Sturzu, S. Sheikh, U. Klose, H. Echner, H. Kalbacher, M. Deeg, T. Nagele, M. Horger, C. Schwentner, U. Ernemann, and S. Heckl, Potential of the gastric motility drug lorglumide in prostate cancer imaging. Eur. J. Pharm. Sci. 45, 575 (2012).
64. A. Anitha, S. Uthaman, S. V. Nair, R. Jayakumar, and V. K. Lakshmanan, Enhanced delivery system of flutamide loaded chitosan-dextran sulphate nanoparticles for prostate cancer. J. Biomed. Nanotechnol. 9, 335 (2013).
65. C. Printz, Drug helps slow advanced prostate cancer. Cancer 118, 4641 (2012).
66. K. Ketola, O. Kallioniemi, and K. Iljin, Chemical biology drug sensitivity screen identifies sunitinib as synergistic agent with disulfiram in prostate cancer cells. Plos One 7 (2012).
67. T. W. Flaig, D. L. Gustafson, L. J. Su, J. A. Zirrolli, F. Crighton, G. S. Harrison, A. S. Pierson, R. Agarwal, and L. M. Glode, A phase I and pharmacokinetic study of silybin-phytosome in prostate cancer patients. Invest. New Drugs 25, 139 (2007).
68. X. Yanyu, S. Yunmei, C. Zhipeng, and P. Qineng, The preparation of silybin-phospholipid complex and the study on its pharmacokinetics in rats. Int. J. Pharm. 307, 77 (2006).
69. S. Giacomelli, D. Gallo, P. Apollonio, C. Ferlini, M. Distefano, P. Morazzoni, A. Riva, E. Bombardelli, S. Mancuso, and G. Scambia, Silybin and its bioavailable phospholipid complex (IdB 1016) potentiate in vitro and in vivo the activity of cisplatin. Life Sci. 70, 1447 (2002).
70. L. Jia, D. Zhang, Z. Li, C. Duan, Y. Wang, F. Feng, F. Wang, Y. Liu, and Q. Zhang, Nanostructured lipid carriers for parenteral delivery of silybin: Biodistribution and pharmacokinetic studies. Colloid Surf. B 80, 213 (2010).
71. B. K. Nanjwade, V. T. Kadam, and F. V. Manvi, Formulation and characterization of nanostructured lipid carrier of ubiquinone (Coenzyme Q10). J. Biomed. Nanotechnol. 9, 450 (2013).
72. E. B. Souto, A. J. Almeida, and R. H. Muller, Lipid nanoparticles (SLN (R), NLC (R)) for cutaneous drug delivery: Structure, protection and skin effects. J. Biomed. Nanotechnol. 3, 317 (2007).
73. Y. T. Xie, Y. Z. Du, H. Yuan, and F. Q. Hu, Brain-targeting study of stearic acid-grafted chitosan micelle drug-delivery system. Int. J. Nanomed. 7, 3235 (2012).
74. L. J. Waters, T. Hussain, and G. M. B. Parkes, Titration calorimetry of surfactant-drug interactions: Micelle formation and saturation studies. J. Chem. Thermodyn. 53, 36 (2012).
75. Y. S. Lai, Y. Y. Long, Y. Lei, X. Deng, B. He, M. M. Sheng, M. Li, and Z. W. Gu, A novel micelle of coumarin derivative monoend-functionalized PEG for anti-tumor drug delivery: In vitro and in vivo study. J. Drug Target. 20, 246 (2012).
76. R. L. Duan, X. Sun, J. Liu, T. Gong, and Z. R. Zhang, Mixed micelles loaded with silybin-polyene phosphatidylcholine complex improve drug solubility. Acta Pharmacol. Sin. 32, 108 (2011).
77. J. N. Yu, Y. A. Zhu, L. Wang, M. Peng, S. S. Tong, X. Cao, H. Qiu, and X. M. Xu, Enhancement of oral bioavailability of the poorly water-soluble drug silybin by sodium cholate/phospholipid-mixed micelles. Acta Pharmacol. Sin. 31, 759 (2010).
78. W. W. Wang, D. Cheng, F. M. Gong, X. M. Miao, and X. T. Shuai, Design of multifunctional micelle for tumor-targeted intracellular drug release and fluorescent imaging. Adv. Mater. 24, 115 (2012).
79. X. Li, Y. Huang, X. Chen, Y. Zhou, Y. Zhang, P. Li, Y. Liu, Y. Sun, J. Zhao, and F. Wang, Self-assembly and characterization of Pluronic P105 micelles for liver-targeted delivery of silybin. J. Drug Target. 17, 739 (2009).
80. R. Machin, J. R. Isasi, and I. Velaz, Beta-cyclodextrin hydrogels as potential drug delivery systems. Carbohyd. Polym. 87, 2024 (2012).
81. F. Lirussi, A. Beccarello, G. Zanette, A. De Monte, V. Donadon, M. Velussi, and G. Crepaldi, Silybin-beta-cyclodextrin in the treatment of patients with diabetes mellitus and alcoholic liver disease. Efficacy study of a new preparation of an anti-oxidant agent. Diabetes Nutr. Metab. 15, 222 (2002).
82. L. Li, T. Yi, and C. W. K. Lam, Interactions between human multidrug resistance related protein (MRP2; ABCC2) and excipients commonly used in self-emulsifying drug delivery systems (SEDDS). In. J. Pharm. 447, 192 (2013).
83. A. Mercuri, A. Passalacqua, M. S. J. Wickham, R. M. Faulks, D. Q. M. Craig, and S. A. Barker, The effect of composition and gastric conditions on the self-emulsification process of ibuprofen-loaded self-emulsifying drug delivery systems: A microscopic and dynamic gastric model study. Pharm. Res. 28, 1540 (2011).
84. A. Niederquell, A. C. Volker, and M. Kuentz, Introduction of diffusing wave spectroscopy to study self-emulsifying drug delivery systems with respect to liquid filling of capsules. Int. J. Pharm. 426, 144 (2012).
85. Y. H. Wei, X. L. Ye, X. G. Shang, X. Peng, Q. Bao, M. C. Liu, M. M. Guo, and F. Z. Li, Enhanced oral bioavailability of silybin by a supersaturatable self-emulsifying drug delivery system (SSEDDS). Colloid Surface A 396, 22 (2012).
86. Y. D. Yan, J. A. Kim, M. K. Kwak, B. K. Yoo, C. S. Yong, and H. G. Choi, Enhanced oral bioavailability of curcumin via a solid lipid-based self-emulsifying drug delivery system using a spray-drying technique. Biol. Pharm. Bull. 34, 1179 (2011).
87. S. Gosangari and T. Dyakonov, Enhanced dissolution performance of curcumin with the use of supersaturatable formulations. Pharm. Dev. Technol. 18, 475 (2013).
88. T. Doane and C. Burda, Nanoparticle mediated non-covalent drug delivery. Adv. Drug Deliver. Rev. 62, 90 (2012).
89. M. Q. Wang, J. X. Zhang, Z. M. Yuan, W. Z. Yang, Q. Wu, and H. C. Gu, Targeted thrombolysis by using of magnetic mesoporous silica nanoparticles. J. Biomed. Nanotechnol. 8, 624 (2012).
90. Y. Z. Zhang, Z. Z. Zhi, T. Y. Jiang, J. H. Zhang, Z. Y. Wang, and S. L. Wang, Spherical mesoporous silica nanoparticles for loading and release of the poorly water-soluble drug telmisartan. J. Control Release 145, 257 (2010).
91. I. I. Slowing, J. L. Vivero-Escoto, C.W.Wu, and V. S. Y. Lin, Mesoporous silica nanoparticles as controlled release drug delivery and gene transfection carriers. Adv. Drug Deliver. Rev. 60, 1278 (2008).
92. X. Cao, W. W. Deng, M. Fu, L. Wang, S. S. Tong, Y. W. Wei, Y. Xu, W. Y. Su, X. M. Xu, and J. N. Yu, In vitro release and in vitro-in vivo correlation for silybin meglumine incorporated into hollow-type mesoporous silica nanoparticles. Int. J. Nanomed. 7, 753 (2012).
93. X. Cao, W. Deng, M. Fu, Y. Zhu, H. Liu, L. Wang, J. Zeng, Y. Wei, X. Xu, and J. Yu, Seventy-two-hour release formulation of the poorly soluble drug silybin based on porous silica nanoparticles: In vitro release kinetics and in vitro/in vivo correlations in beagle dogs. Eur. J. Pharm. Sci. 48, 64 (2012).
94. T. M. Fu, J. Lu, L. W. Guo, L. J. Zhang, X. P. Cal, and H. X. Zhu, Improving bioavailability of silybin by inclusion into SBA-15 mesoporous silica materials. J. Nanosci. Nanotechnol. 12, 3997 (2012).
95. D. A. Tomalia, M. Hall, and D. M. Hedstrand, Starburst dendrimers3 the importance of branch junction symmetry in the development of topological shell molecules. J. Am. Chem. Soc. 109, 1601 (1987).
96. S. R. Pan, D. W. Cao, W. Yi, H. Huang, and M. Feng, A biodegradable and serum-resistant gene delivery carrier composed of polyamidoamine-poly N, N′-di-(2-aminoethyl)aminoethyl glutamine copolymer. Colloid Surfaces B 104, 294 (2013).
97. Z. Q. Dong, H. Katsumi, T. Sakane, and A. Yamamoto, Effects of polyamidoamine (PAMAM) dendrimers on the nasal absorption of poorly absorbable drugs in rats. Int. J. Pharm. 393, 244 (2010).
98. D. S. Pisal, V. K. Yellepeddi, A. Kumar, R. S. Kaushik, M. B. Hildreth, X. M. Guan, and S. Palakurthi, Permeability of surface-modified polyamidoamine (PAMAM) dendrimers across Caco-2 cell monolayers. Int. J. Pharm. 350, 113 (2008).
99. X. Huang, Z. H. Wu, W. Gao, Q. Chen, and B. Yu, Polyamidoamine dendrimers as potential drug carriers for enhanced aqueous solubility and oral bioavailability of silybin. Drug Dev. Ind. Pharm. 37, 419 (2011).
100. S. Sadekar and H. Ghandehari, Transepithelial transport and toxicity of PAMAM dendrimers: Implications for oral drug delivery. Adv. Drug Deliver. Rev. 64, 571 (2012).
101. A. R. Menjoge, A. L. Rinderknecht, R. S. Navath, M. Faridnia, C. J. Kim, R. Romero, R. K. Miller, and R. M. Kannan, Transfer of PAMAM dendrimers across human placenta: Prospects of its use as drug carrier during pregnancy. J. Control Release 150, 326 (2011).
102. H. Al-Obaidi, M. J. Lawrence, S. Shah, H. Moghul, N. Al-Saden, and F. Bari, Effect of drug-polymer interactions on the aqueous solubility of milled solid dispersions. Int. J. Pharm. 446, 100 (2013).
103. E. Broman, C. Khoo, and L. S. Taylor, A comparison of alternative polymer excipients and processing methods for making solid dispersions of a poorly water soluble drug. Int. J. Pharm. 222, 139 (2001).
104. J. J. Moes, S. L. W. Koolen, A. D. R. Huitema, J. H. M. Schellens, J. H. Beijnen, and B. Nuijen, Pharmaceutical development and preliminary clinical testing of an oral solid dispersion formulation of docetaxel (ModraDoc001). Int. J. Pharm. 420, 244 (2011).
105. J. X. Wu, M. S. Yang, F. van den Berg, J. Pajander, T. Rades, and J. Rantanen, Influence of solvent evaporation rate and formulation factors on solid dispersion physical stability. Eur. J. Pharm. Sci. 44, 610 (2011).
106. W. W. Yao, T. C. Bai, J. P. Sun, C. W. Zhu, J. Hu, and H. L. Zhang, Thermodynamic properties for the system of silybin and poly(ethylene glycol) 6000. Thermochim. Acta 437, 17 (2005).
107. X. Han, C. Ghoroi, D. To, Y. H. Chen, and R. Dave, Simultaneous micronization and surface modification for improvement of flow and dissolution of drug particles. Int. J. Pharm. 415, 185 (2011).
108. Z. B. Zhang, Z. G. Shen, J. X. Wang, H. X. Zhang, H. Zhao, J. F. Chen, and J. Yun, Micronization of silybin by the emulsion solvent diffusion method. Int. J. Pharm. 376, 116 (2009).